ClinicalTrials.gg
RecruitingNCT07836465ENGAGEUpdated Nov 16, 2026

A Pilot Study to Explore the Feasibility of Navigator and Coach Support for Community Participation by Older People

An interventional study of Navigation support and Coaching support in Frailty, Social Isolation in Older Adults and Frailty in Older Adults, sponsored by Bastiaan Van Grootven. Recruiting at 1 site in Switzerland. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Bastiaan Van Grootven · Not applicable, Interventional, and Health services research

Updated Nov 16, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Frailty with a site in Switzerland — 9 open to participants now, 10 under way, none of them phase 3. Frailty · Switzerland.

Planned enrollment
9th of 10
45 · median 120
Started
2026
with 1 other
No phase
9 of 21
5 open now
Registered
21st of 21
by date
Lead sponsor
1 of 21
Bastiaan Van Grootven

Among the 21 studies in Frailty with a site in Switzerland, this one is the 9th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2026, is one of 9 with no phase, and was the 21st registered.

Frailty

1,287 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

9 of the 21 studies in Frailty with a site in Switzerland are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 301 Frailty studies recruiting now, 236 (78%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 67 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Frailty with a site in Switzerland, or all of them as a file.
02

Study summary

Frailty is a multidimensional syndrome in which a person accumulates age-related deficits across life domains, increasingly including social components such as social isolation. An estimated 12% of the Swiss population aged 65+ is frail and a further 46% pre-frail; without prevention, about two thirds of pre-frail persons will become frail, with major consequences for disability, hospitalisation, mortality, quality of life and health costs. Meta-analyses identify physical activity as the most promising prevention strategy, yet structured mechanisms connecting older adults with existing community activities remain underdeveloped and fragmented. To close this implementation gap, the ENGAGE implementation project co-designed a community participation support pathway with local stakeholders: older adults with low physical and/or social activity are systematically identified during routine contacts, a values-based conversation clarifies what matters to the person, the person is matched and referred to existing community activities, and a navigator (a social work professional acting as link worker) provides behavioural, practical and emotional support for initial and continued participation. Because there are uncertainties in the delivery of the study and intervention, a pilot study with a pragmatic randomised trial design is implemented.

03

Conditions studied

  • Frailty
  • Social Isolation in Older Adults
  • Frailty in Older Adults

Browse trials for

Keywords

  • Pilot study
  • Pragmatic trial
  • Social prescribing
  • Behavioural change
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥65 years
  • Community-dwelling in Basel-Stadt/Basel-Landschaf
  • Low levels of physical activity and/or low levels of social activity or perceptions of social isolation
  • Sufficient German to understand the study information
  • Give written

Exclusion criteria

Exclusion Criteria:

  • Residing in residential long-term care
  • Inability to move outside the home without another person's assistance (mobility aids and transport services are permitted)
  • Participation in a conflicting study
  • Severe cognitive impairment, severe psychiatric illness, communication barrier or sensory impairment precluding or meaningful engagement
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • No intervention
    Standard of care

    Participants remain free to receive usual care, professional advice, community information and community services that would normally be available outside the study.

  • Experimental
    Navigation support

    In intervention arm 1, patients are connected with a navigator. The navigator is a social worker trained to conduct a needs assessment and support an older person in finding and attending an appropriate community activities/services.

    Behavioral: Navigation support

  • Experimental
    Navigation and support support

    In intervention arm 2, patients are connected with a navigator and a coach. Navigator support in this arm will be the same as for intervention arm 1, while the coaching will be provided by a trained member of the trial team. Coaching will follow-up on the initial navigation support, and will include a more intensive behavioural support.

    Behavioral: Navigation support · Behavioral: Coaching support

Interventions

  • BehavioralNavigation support

    The navigator conducts a needs assessment and support an older person in finding and attending an appropriate community activities/services. They can offer a brief and limited set of behavioral change techniques (such as information about health consequences, goal setting, action planning, and discussing barriers) to support attendance and provide follow-up.

  • BehavioralCoaching support

    Coaching will follow-up on the initial navigation support (e.g., needs elicitation, activity matching, goal setting, action planning), and will include a more intensive behavioural support. This will be based on motivational interviewing, which is used to conduct a live behavioural diangnosis using the COM-B model, and subsequent selection of one or more appropriate behavioural change techniques, individualised to the participant.

06

What researchers measure

Primary outcomes

  1. Progression decision to full trial

    The primary endpoint for the pilot is the overall progression decision after the internal pilot, classified as: proceed to the full RCT without modifications; proceed with modifications; or stop.

    Time frame: From enrollment until month 3

Secondary outcomes

  1. Feasibility of start-up procedures

    The endpoint will be expressed as the number and type of problems identified per procedure domain (recruitment, consent, home-visit procedures, baseline assessment, data entry, randomisation, communication with study partners, and preparation for intervention initiation). Problems will be categorised as minor operational issue, major operational issue requiring procedure change, or critical issues requiring amendments to the ethics dossier.

    Time frame: From study enrolment until randomisation at around 2 weeks

  2. Number of potential participants screened, recruited, randomised and retained

    The endpoint will be expressed as the number and proportion of potential participants identified, screened, eligible, consented, randomised, and retained until the month 3 follow-up.

    Time frame: From enrollment until month 3

  3. Reasons for refusal, discontinuation, withdrawal or loss to follow-up

    The endpoint will be expressed as the number and proportion of reasons for non-participation, discontinuation of the allocated pathway, withdrawal from study procedures, withdrawal of consent, and loss to follow-up where available.

    Time frame: From enrollment until month 3

  4. Completeness of full-trial outcome data

    The endpoint will be expressed as the number and proportion of participants with complete data per instrument and timepoint for the primary and key secondary full trial endpoints.

    Time frame: From enrollment until month 3

  5. Parameters informing the full-trial sample-size assumptions:

    The endpoint will be expressed as the observed standard deviation of the Tilburg Frailty Indicator at month 3, the observed residual standard deviation, the correlation between baseline and month 3 scores, and case-load per Navigator.

    Time frame: From enrollment until month 3

  6. Contamination between study arms

    The endpoint will be expressed as the number and proportion of participants per arm with documented contamination, categorised by type and source, with a short qualitative summary.

    Time frame: From enrollment until month 6

  7. Adoption of the ENGAGE Pathway: number and percentage of approached organisations and individual deliverers reaching each adoption Stage.

    The endpoint will be expressed, per implementation region, as: 1) the number and proportion of approached organisations and individual deliverers progressing through each stage of adoption; and 2) the number and type of operational deliverers and case-finding routes. The endpoint will be measured using the ENGAGE Implementation Logbook.

    Time frame: From enrolment until month 3

  8. Implementation-Strategy Fidelity: number and percentage of prespecified implementation strategies delivered as planned, partially delivered, or not delivered.

    Implementation-strategy fidelity is defined as the degree to which the research team delivered the prespecified implementation strategies as specified, against each strategy's prespecified actor, action, dose and temporality. The endpoint will be expressed as: 1) the number and proportion of prespecified implementation strategies classified as delivered as planned, partially delivered, or not delivered; and 2) the reasons for partial or non-delivery. The endpoint will be measured using the ENGAGE Implementation Logbook.

    Time frame: From enrolment until month 3

  9. Implementer experience and perceptions:

    The endpoint will be expressed as a thematic summary and recommended adaptations for the full trial.

    Time frame: From enrollment until month 3

  10. Delivered dose and participant responsiveness: number and percentage of participants achieving each engagement milestone, and number and duration of navigator and coaching contacts received.

    Delivered dose is the number, mode, content and duration of navigator and coaching contacts provided to participants. Participant responsiveness is the degree to which participants engage with the support and the activities, covering enrolment in, first attendance at, and continued participation in community activities; discontinuation; and engagement with navigator and coaching contacts. The endpoint will be expressed, separately by study arm, as: 1) the number and proportion of participants achieving each engagement milestone; and 2) the number and duration (minutes) of navigator and coaching contacts received per participant. The endpoint will be measured using the ENGAGE Intervention Logbook.

    Time frame: From enrollment until month 3

  11. Participant experience, perceived value and determinants of participation

    The endpoint will be expressed as a thematic summary of participant experience.

    Time frame: From enrollment until month 3

07

Study locations

1 of 1 sites recruiting
  • Institute of Nursing Science
    Basel, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — The endpoints in this pilot study concern feasibility indicators. The results in itself provide the full data. If a progression to the full trial is made, a separate registration with IPD will be made.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Sep 2027, 11 months after the start.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 11 months is below that.

Counting every sponsor, half of 518 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2026
First posted
Sep 23, 2026
StartActual
Oct 24, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
Institute of Nursing Science is now Recruiting
Nov 16, 2026
Start date
Oct 1, 2026→Oct 24, 2026 (actual)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    Institute of Nursing Science is now Recruiting
    Start date Oct 1, 2026→Oct 24, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07836465
Lead sponsor
Bastiaan Van Grootven
Collaborators
University of Basel
Responsible party
Bastiaan Van Grootven (SNF Ambizione Fellow, University of Basel) — Sponsor-investigator
First posted
Sep 23, 2026
Start date
Oct 24, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Bastiaan Van Grootven
principal investigator · University of Basel - Public Health - Nursing Science

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion